Compass is still being developed and is effectively in beta. Some content and features may be incomplete, change, or not work as expected.

Content is anchored to trusted sources where available, but Compass has not yet been clinically reviewed. It provides general information rather than medical advice.

Feedback helps us identify gaps, errors, usability problems and opportunities to improve Compass over time.

How Compass is developedGive feedback

Phase 2 trial of 50 mg Usnoflast opens to recruitment

Original source

Phase 2 trial of 50 mg Usnoflast opens to recruitmentClinicalTrials.gov · 28 July 2026 (opens in a new tab)

Trial at a glance

Status
Recruiting
Phase
Phase 2
Intervention
50 mg Usnoflast (drug)
Enrolment
240 participants (estimated)
Sites
Canada, the United States
Sponsor
Zydus Therapeutics Inc.
Registration
NCT07023835

Compass reports what the trial registry states. A trial being registered, recruiting or completed is not evidence that a treatment works.

This recruiting Phase 2 interventional study is testing 50 mg and 75 mg Usnoflast in people with amyotrophic lateral sclerosis. It has sites in Canada and the United States, with estimated enrolment of 240 participants. The registry change is that recruitment has opened.

Why this matters

Recruitment opening means eligible people in Canada and the United States may be able to take part. The registry does not report posted results.

Trial updates

Recruitment opened — 28 July 2026

Compass began tracking this trial’s registry record on the date of its first update above. Changes before then are not listed.

Summarised by Compass 30 August 2026 · reported from Canada and the United States

This summary was generated by AI from the source listed above. It is not medical advice, so read the original source for anything that affects your care.

Relevant to you?